Pictet Asset Management Ltd. raised its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.0% in the 1st quarter, Holdings Channel reports. The fund owned 396,476 shares of the biopharmaceutical company’s stock after purchasing an additional 109,206 shares during the quarter. Pictet Asset Management Ltd.’s holdings in PTC Therapeutics were worth $14,923,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PTCT. NumerixS Investment Technologies Inc bought a new stake in shares of PTC Therapeutics in the 4th quarter valued at $32,000. Canton Hathaway LLC increased its holdings in PTC Therapeutics by 57.1% during the 4th quarter. Canton Hathaway LLC now owns 1,100 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in PTC Therapeutics by 34.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,732 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 696 shares in the last quarter. US Bancorp DE increased its holdings in PTC Therapeutics by 9.3% during the 1st quarter. US Bancorp DE now owns 3,115 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 264 shares in the last quarter. Finally, Smith Asset Management Group LP bought a new position in PTC Therapeutics during the 4th quarter worth about $184,000.

PTC Therapeutics stock opened at $39.95 on Tuesday. PTC Therapeutics, Inc. has a one year low of $27.53 and a one year high of $52.95. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.35 and a quick ratio of 3.24. The stock has a market cap of $2.34 billion, a PE ratio of -21.71 and a beta of 1.78.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.55). PTC Therapeutics had a negative return on equity of 32.42% and a negative net margin of 68.99%. The business had revenue of $53.58 million for the quarter, compared to analyst estimates of $70.38 million. During the same quarter in the prior year, the company earned ($0.46) earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis. On average, sell-side analysts expect that PTC Therapeutics, Inc. will post -2.54 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. ValuEngine upgraded PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, May 10th. Zacks Investment Research cut PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a report on Thursday, May 2nd. Bank of America upgraded shares of PTC Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $43.00 to $49.00 in a research note on Monday, May 13th. Finally, Sanford C. Bernstein started coverage on shares of PTC Therapeutics in a research note on Thursday, April 11th. They set an “outperform” rating and a $48.00 price objective for the company. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. PTC Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $49.89.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/pictet-asset-management-ltd-acquires-109206-shares-of-ptc-therapeutics-inc-ptct/3031210.html.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Featured Article: Closed-End Mutual Funds

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.